tiprankstipranks
Trending News
More News >

Entrada Therapeutics price target lowered to $21 from $23 at Roth Capital

Roth Capital analyst Boobalan Pachaiyappan lowered the firm’s price target on Entrada Therapeutics (TRDA) to $21 from $23 and keeps a Buy rating on the shares after discussing the progress of the company’s DMD clinical programs. The firm remains enthusiastic about ENTR-601-44 and ENTR-601-45, looking forward to the respective clinical trial starts in the U.S. and ex-U.S. regions, though also acknowledges the latter’s clinical trajectory could be “long and winding”, the analyst tells investors in a research note.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue